University of Washington

Health Systems and Population Health

SCHOOL OF PUBLIC HEALTH

Faculty Member


  1. Home


  2. About


  3. Meet the Faculty


  4. Faculty Member

Sean D Sullivan photo

Sean D Sullivan

Professor, Health Systems and Population Health
Professor, Pharmacy
Adjunct Professor, Medicine – Allergy and Infectious Dis.

206-685-8153 | sdsull@uw.edu

Office H-375, Health Sciences Building
Box 357630
1959 NE Pacific Street, Seattle, WA 98195

Research Interests

Technology assessment; medical decision making; economic evaluation of pharmaceuticals, particularly in the areas of respiratory disorders, organ transplantation, HIV/AIDS, mental health and clinical decision making

Bio

Sean D. Sullivan is Professor and Dean of the University of Washington School of Pharmacy. In addition to his joint appointment as Professor of Health Services, He also holds adjunct appointments in the School of Medicine, the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, and at Kaiser Permanente Washington Health Research Institute.

Dr. Sullivan has authored more than 400 journal articles, book chapters, task force reports and organizational and governmental publications. In many of these, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include technology assessment, medical decision-making and economic evaluation of medical technology. He is past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) executive committee of the Format for Formulary Submissions – the United States evidence-based guidelines for formulary decision-making.

Dr. Sullivan served as a member of the Medicare Evidence Development and Coverage Advisory Committee, a member of the Regence Blue Shield and Premera Blue Cross P/T Committee and chair, Premera Blue Cross Value Assessment Committee. He is also on the editorial boards of Value in Health, PharmacoEconomics, and Journal of Medical Economics. He was awarded the 2014 Stephen G. Avey Lifetime Achievement Award from the Academy of Managed Care Pharmacy and the 2015 APhA Academy of Pharmaceutical Research Sciences (APRS) Research Achievement Award.

Education

PhD Health Economics, University of California (Berkeley), 1992
MS Pharmacy, University of Texas (Austin), 1986
BS Pharmacy, Oregon State University, 1983

Academic Programs and Affiliations

Recent Publications (PubMed)

The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
PubMed
Suh K, Carlson JJ, Xia F, Williamson T, Sullivan SD. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. J Manag Care Spe
Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study.
PubMed
Briggs A, Wehler B, Gaultney JG, Upton A, Italiano A, Bokemeyer C, Paracha N, Sullivan SD. Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study. Value
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments.
PubMed
Sullivan SD, Sullivan KD, Dabbous O, Garrison LP. International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments. J Manag Care Spec Pharm. 2022 May;28(5):566-572. doi: 10.18553/jmcp.2022.28.5.566.
Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD.
PubMed
Watabayashi KK, Bell-Brown A, Kreizenbeck K, Egan K, Lyman GH, Hershman DL, Arnold KB, Bansal A, Barlow WE, Sullivan SD, Ramsey SD. Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learn
Cost-Effectiveness of the COVID-19 Test, Trace and Isolate Program in Colombia.
PubMed
Guzmán Ruiz Y, Vecino-Ortiz AI, Guzman-Tordecilla N, Peñaloza-Quintero RE, Fernández-Niño JA, Rojas-Botero M, Ruiz Gomez F, Sullivan SD, Trujillo AJ. Cost-Effectiveness of the COVID-19 Test, Trace and Isolate Program in Colombia. Lancet Reg Health Am. 202
Diagnosis and management of TRK fusion cancer.
PubMed
Kummar S, Italiano A, Brose MS, Carlson JJ, Sullivan SD, Lassen U, Federman N. Diagnosis and management of TRK fusion cancer. Am J Manag Care. 2022 Jan;28(2 Suppl):S15-S25. doi: 10.37765/ajmc.2022.88834. Review.
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
PubMed
Carlson JJ, Italiano A, Brose MS, Federman N, Lassen U, Kummar S, Sullivan SD. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. Am J Manag Care. 2022 Jan;28(2 Suppl):S26-S32. doi: 10.37765/ajmc.2022.88845. Review.
Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe.
PubMed
Tunis S, Hanna E, Neumann PJ, Toumi M, Dabbous O, Drummond M, Fricke FU, Sullivan SD, Malone DC, Persson U, Chambers JD. Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. Health Policy. 2021 Dec
FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes.
PubMed
Pochopień MT, Cherney DZI, Folkerts K, Levy P, Millier A, Morris S, Roy-Chaudhury P, Sullivan SD, Mernagh P. FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2021 Dec;27(
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study.
PubMed
Briggs A, Paracha N, Rosettie K, Upton A, Bokemeyer C, Lassen U, Sullivan SD. Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study. Oncology. 2022;100(2):124-130. doi: 10.1159/000519767. Epub 2021 Nov 29.

More Publications